路云龙 (邮箱: yunlonglu12@njucm.edu.cn)，博士，副教授，硕士研究生导师。本硕就读于中国药科大学，博士毕业于美国伊利诺伊大学芝加哥分校，现任教于bwin必赢药理系，中国化学会会员。
主要研究领域包括：抗肿瘤靶向治疗小分子药物研发与药理机制研究。主要针对乳腺癌，肝癌和肺癌等重大疾病，基于靶标进行合理药物设计与合成，对药理机制进行深入研究。目前以第一或通讯作者发表SCI论文15篇，收录于J Med Chem, Eur J Med Chem, Pharm Res, Chin Chem Lett, Chem Soc Rev等期刊，撰写ELSEVIER书籍章节，申请国家发明专利2项，授权国际专利2项。目前主持国家自然科学基金青年基金，江苏省教育厅，江苏省卫健委等基金项目，Biomedicine & Pharmacotherapy等期刊审稿人。
代表性研究论文
1.Yunlong Lu#, Chao Liu#, Xin Wang#, Lijuan Liu, Zhihao Zhao, Zhenlin Liang, Yuanhao Liu, Zhenfan Wen, Qianming Du* and Wukun Liu*. Design, synthesis and biological evaluation of fluorinated selective estrogen receptor degraders (FSERDs) - A promising strategy for advanced ER positive breast cancer. Eur. J. Med. Chem. 2023, 253, 115324.
2.Yunlong Lu#, Yuanhao Liu#, Zhenlin Liang, Xiaoyan Ma, Lijuan Liu, Zhenfan Wen, Iogann Tolbatov, Alessandro Marrone and Wukun Liu* NHC-gold(I)-alkyne complexes induced hepatocellular carcinoma cell death through bioorthogonal activation by palladium complex in living system. Chin. Chem. Lett. 2023, 34, 9, 108413.
3. Yunlong Lu, Xinyu Sheng, Chao Liu, Zhenlin Liang, Xin Wang, Lijuan Liu, Zhenfan Wen, Zhibin Yang, Qianming Du* and Wukun Liu* SERD-NHC-Au(I) complexes for dual targeting ER and TrxR to induce ICD in breast cancer. Pharmacol. Res. 2023, 190, 106731.
4. Yunlong Lu, Xiaoyan Ma, Xingyu Chang, Zhenlin Liang, Lin Lv, Min Shan, Qiuyue Lu, Zhenfan Wen, Ronald Gust* and Wukun Liu*. Recent development of gold(I) and gold(III) complexes as therapeutic agents for cancer diseases. Chem. Soc. Rev. 2022, 51, 5518 -5556.
5. Yunlong Lu#, Lauren Gutgesell#, Rui Xiong, Jiong Zhao, Yangfeng Li, Carlo Rosales, Michael Hollas, Zhengnan Shen, Jesse Gordon-Blake, Katherine Dye, Yueting Wang, Sue Lee, Hu Chen, Donghong He, Oleksii Dubrovyskyii, Huiping Zhao, Fei Huang, Amy W. Lasek, Debra A. Tonetti, and Gregory R. J. Thatcher*. Design and synthesis of basic selective estrogen receptor degraders for endocrine therapy resistant breast cancer. J. Med. Chem., 2019, 62, 24, 11301-11323.
